The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS: We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group versus the ipilimumab group. RESULTS: At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]). The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group. The safety profile was unchanged from the initial report. Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. CONCLUSIONS: Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone. (Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“3-year overall survival rates were 58%, 52%, and 34% in combination therapy, anti-PD-1, and anti-CTLA-4 groups, respectively [4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [4]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These chemokines have been identified as the dominant mediators for the recruitment of CXCR3+ and CCR5+ tumor-specific T lymphocytes into the tumors and their intratumoral expression correlated with favorable clinical outcomes in patients with melanoma30–32.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [36]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 9×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 6×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 9×
“Increased amylase level 26 (8) 9 (3) 20 (6) 6 (2) 15 (5) 4 (1)”
InfluentialSelf-citationTime‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · cited 8×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Robert C, 2017, J Clin Oncol, 15, 35
- Long GV, Ann Oncol
Cited by
Sorted by citations
Items 901–1,000 of 1,021
Vijayakumar, G., Palese, P., & Goff, P. H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.032 · Cited by 67
“[12] Wolchok JD , Chiarion-Sileni V , Gonzalez R , Rutkowski P , Grob JJ , Cowey CL , et al.”
BackgroundCaccese, M., Barbot, M., Ceccato, F., Padovan, M., Gardiman, M. P., Fassan, M., Denaro, L., Emanuelli, E., D’Avella, D., Scaroni, C. M., et al. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000856 · Cited by 68
Shafqat, H., Gourdin, T. S., & Sion, A. M. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.07.003 · Cited by 68
Friedrich, M., Jasinski‐Bergner, S., Lazaridou, M., Subbarayan, K., Massa, C., Tretbar, S., Müeller, A., Handke, D., Biehl, K., Bukur, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02373-1 · Cited by 68
Fukuoka, E., Yamashita, K., Tanaka, T., Sawada, R., Sugita, Y., Arimoto, A., Fujita, M., Takiguchi, G., Matsuda, T., Oshikiri, T., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13631 · Cited by 66
Pearson, A. D. J., Rössig, C., Lesa, G. M., Diede, S. J., Weiner, S. L., Anderson, J., Gray, J. C., Geoerger, B., Minard‐Colin, V., Marshall, L. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.12.029 · Cited by 68
Quagliariello, V., Passariello, M., Rea, D., Barbieri, A., Iovine, M., Bonelli, A., Caronna, A., Botti, G., Lorenzo, C. D., & Maurea, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040179 · Cited by 68
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Halle, B. R., Warner, A. B., Zaman, F. Y., Haydon, A. M., Bhave, P., Dewan, A. K., Ye, F., Irlmeier, R. T., Mehta, P. P., Kurtansky, N. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003066 · Cited by 67
Self-citationEfficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Bhave, P., Ahmed, T., Lo, S., Shoushtari, A. N., Zaremba, A., Versluis, J. M., Mangana, J., Weichenthal, M., Si, L., Lesimple, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004668 · Cited by 67
Self-citationYu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68
Amoroso, V., Gallo, F., Alberti, A., Paloschi, D., Bravo, W. F., Esposito, A., Cosentini, D., Grisanti, S., Pedersini, R., Petrelli, F., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100787 · Cited by 70
“26) Wolchok et al.(44) Melanoma Nivolumab Ipilimumab 631 >36.”
BackgroundPark, J., Kwon, M., Kim, K. H., Kim, T.-S., Hong, S.-H., Kim, C. G., Kang, S., Moon, J. H., Kim, E. H., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2564 · Cited by 68
“Clin Cancer Res; 25(8) April 15, 2019 Clinical Cancer Research 2554”
BackgroundInfluentialA Review of the Role of Wnt in Cancer Immunomodulation
Goldsberry, W. N., Londoño, A. I., Randall, T. D., Norian, L. A., & Arend, R. C. (2019) · Cancers · doi:10.3390/cancers11060771 · Cited by 67
“Further improvements in metastatic melanoma were seen following a combination of ipilimumab and anti-PD-L1 therapy [98].”
BackgroundImmune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
Herrscher, H., & Robert, C. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000610 · Cited by 70
Reverting Immune Suppression to Enhance Cancer Immunotherapy
Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 71
“The clinical study NCT01454102 (CheckMate 012) testing the combination of nivolumab plus ipilimumab as first line treatment for advanced NSCLC patients showed durable efficacy and resulted in a significantly longer OS than ipilimumab alone in a phase III trial involving patients with advanced melanoma [CheckMate 067,…”
BackgroundThe Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
Cabrita, R., Mitra, S., Sanna, A., Ekedahl, H., Lövgren, K., Olsson, H. L., Ingvar, C., Isaksson, K., Lauss, M., Carneiro, A., et al. (2020) · Cancers · doi:10.3390/cancers12030742 · Cited by 69
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Kotanides, H., Li, Y. H., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I. V., Surguladze, D., Pennello, A. L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0304 · Cited by 66
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
Patrinely, J. R., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D. E., Horst, S., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1875639 · Cited by 68
Self-citationParra, E. R., Ferrufino‐Schmidt, M. C., Tamegnon, A., Zhang, J., Solis, L. M., Jiang, M., Ibarguen, H. P., Haymaker, C., Lee, J. J., Bernatchez, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88156-0 · Cited by 66
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
Filipski, K., Scherer, M., Zeiner, K. N., Bucher, A. M., Kleemann, J., Jurmeister, P. S., Hartung, T. I., Meißner, M., Plate, K. H., Fenton, T. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002226 · Cited by 64
Watson, A., Goutam, S., Stukalin, I., Ewanchuk, B. W., Sander, M. S., Meyers, D. E., Pabani, A., Cheung, W. Y., Heng, D. Y. C., Cheng, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45596 · Cited by 69
“9) Cycles received, median (range) 6 (3-13) 6 (3-14)”
Wang, Y., Zhou, S., Wang, Y., Lu, Z.-D., Zhang, Y., Xu, C., & Wang, J. (2023) · Nature Communications · doi:10.1038/s41467-023-37656-w · Cited by 67
Váraljai, R., Zimmer, L., Al-Matary, Y. S., Kaptein, P., Albrecht, L. J., Shannan, B., Brase, J. C., Gusenleitner, D., Amaral, T. M. S., Wyss, N., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00610-2 · Cited by 70
Self-citationMelanoma Immunotherapy: Next-Generation Biomarkers
Hogan, S. A., Levesque, M. P., & Cheng, P. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00178 · Cited by 68
“Response rates for ipilimumab range from 11% to 19% (4, 5) and for pembrolizumab or nivolumab from 33% to 44% (2, 6, 7).”
BackgroundEnhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles
Bulner, S., Prodeus, A., Gariépy, J., Hynynen, K., & Goertz, D. E. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.10.002 · Cited by 67
Wodlej, C., Riedl, S., Rinner, B., Leber, R., Drechsler, C., Voelker, D. R., Choi, J., Lohner, K., & Zweytick, D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211187 · Cited by 66
Chen, H., Yang, M., Wang, Q., Song, F., Li, X., & Chen, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608132 · Cited by 66
Kato, S., Okamura, R., Kumaki, Y., Ikeda, S., Nikanjam, M., Eskander, R. N., Goodman, A. M., Lee, S., Glenn, S. T., Dressman, D. C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1708065 · Cited by 68
“52% in the nivolumab group).(24) In the field of genomics, there are several remarkable successes with the use of targeted drugs.”
BackgroundBaxi, V., Lee, G., Duan, C., Pandya, D., Cohen, D. N., Edwards, R., Chang, H., Li, J., Elliott, H., Pokkalla, H., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01119-2 · Cited by 66
Oyanagi, J., Koh, Y., Sato, K., Mori, K. P., Teraoka, S., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.020 · Cited by 66
Kao, H., & Lou, P. (2019) · Head & Neck · doi:10.1002/hed.25930 · Cited by 66
Conjunctival Melanoma: Current Treatments and Future Options
Grimes, J. M., Shah, N. V., Samie, F. H., Carvajal, R. D., & Marr, B. P. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00500-3 · Cited by 67
“Common adverse effects in larger studies of ipilimumab in cutaneous melanoma include rash, pruritis, fatigue, diarrhea, nausea, and reduced appetite [100].”
BackgroundXing, Q., Zhang, Z., Lin, Q., Shen, L., Wang, P., Zhang, S., Fan, M., & Zhu, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.79 · Cited by 62
“The application of immune checkpoint inhibitors (ICIs) has ushered a new era for cancer therapy and shown the efficacy of improving the survival time for patients with advanced malignancies, such as non-small cell lung cancer and metastatic melanoma (1,2).”
BackgroundXu, Z., Tsai, H., Xiao, Y., Wu, Y., Su, D., Yang, M., Zha, H., Yan, F., Liu, X., Cheng, F., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09065 · Cited by 65
Drakaki, A., Dhillon, P. K., Wakelee, H. A., Chui, S. Y., Shim, J., Kent, M., Degaonkar, V., HOANG, T. N., McNally, V. A., Luhn, P., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1824645 · Cited by 65
Marsavela, G., Lee, J., Calapre, L., Wong, S. Q., Pereira, M. R., McEvoy, A. C., Reid, A. L., Robinson, C., Warburton, L., Abed, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2251 · Cited by 66
Self-citationReynolds, A. C., & McKenzie, L. J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01885 · Cited by 68
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 68
NLRP3 and cancer: Pathogenesis and therapeutic opportunities
Tengesdal, I. W., Dinarello, C. A., & Marchetti, C. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108545 · Cited by 70
Hegewisch‐Becker, S., Mendez, G. A., Chao, J., Němeček, R., Feeney, K., Cutsem, E. V., Al‐Batran, S., Mansoor, W., Maisey, N. R., Pazo-Cid, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01636 · Cited by 68
Melanoma and Immune Checkpoint Inhibitors
Furue, M., Ito, T., Wada, N. A., Wada, M., Kadono, T., & Uchi, H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0676-z · Cited by 67
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Hantel, A., Gabster, B. P., Cheng, J. X., Golomb, H. M., & Gajewski, T. F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0384-0 · Cited by 65
The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy
Kulasinghe, A., Wu, H., Punyadeera, C., & Warkiani, M. E. (2018) · Micromachines · doi:10.3390/mi9080397 · Cited by 67
Steeb, T., Wessely, A., Ruzicka, T., Heppt, M. V., & Berking, C. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.005 · Cited by 65
Caparica, R., Lambertini, M., Ponde, N. F., Fumagalli, D., de Azambuja, E., & Piccart, M. J. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919827714 · Cited by 66
Nivolumab and Ipilimumab in Advanced Melanoma
Alegre-del-Rey, E. J., Fernández, B. D. L. N., & Briceño-Casado, P. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1714339 · Cited by 65
Therapeutic Targets for Bone and Soft-Tissue Sarcomas
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010170 · Cited by 66
Kümpers, C., Jokić, M., Haase, O., Offermann, A., Vogel, W., Grätz, V., Langan, E. A., Perner, S., & Terheyden, P. A. M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00027 · Cited by 65
“We found no significant correlations in either setting (9).”
BackgroundCD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
Richardson, J. R., Schöllhorn, A., Gouttefangeas, C., & Schuhmacher, J. (2021) · Cancers · doi:10.3390/cancers13040596 · Cited by 66
“In a larger recent study including 60 selected patients with tumors of high mutational load (NSCLC, melanoma, and bladder carcinoma), a combination of PD-1 blockade with individual multi-SLP vaccines showed an excellent safety profile, and induced the development of CD8+ and CD4+ neoantigen-specific effector T cells (…”
BackgroundInfluentialCombining nanomedicine and immune checkpoint therapy for cancer immunotherapy
Boone, C. E., Wang, L., Gautam, A., Newton, I. G., & Steinmetz, N. F. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1739 · Cited by 66
Dousset, L., Poizeau, F., Robert, C., Mansard, S., Mortier, L., Caumont, C., Routier, É., Dupuy, A., Rouanet, J., Battistella, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00084 · Cited by 71
Self-citationJin, W., Yang, Q., Chi, H., Wei, K., Zhang, P., Zhao, G., Chen, S., Xia, Z., & Li, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025330 · Cited by 64
Recent advances and future perspectives in the therapeutics of prostate cancer
Varaprasad, G. L., Gupta, V., Prasad, K., Kim, E., Tej, M. B., Mohanty, P., Verma, H. K., Raju, G. S. R., Bhaskar, L. V., & Huh, Y. S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00444-9 · Cited by 72
“The synergistic effect of anti-D-1/PD-L1 and anti-CTLA-4 has been reported in renal cancer and melanoma [204, 205].”
BackgroundYin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Clinical characterization of colitis arising from anti-PD-1 based therapy
Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R. J., Silk, A. W., Zhou, A. Y., Compton, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1524695 · Cited by 66
“included in the combination therapy cohort since the frequency of irAEs appears similar between sequential and concurrent nivolumab and ipilimumab.(25,27) Patient data was collected from Georgetown University (n = 13), Massachusetts General Hospital (n = 29), Moffitt Cancer Center (n = 19), Northwestern University (n…”
BackgroundSelf-citationPrognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
Okadome, K., Baba, Y., Nomoto, D., Yagi, T., Kalikawe, R., Harada, K., Hiyoshi, Y., Nagai, Y., Ishimoto, T., Iwatsuki, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0811-0 · Cited by 65
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Bhave, P., Pallan, L., Long, G. V., Menzies, A. M., Atkinson, V. G., Cohen, J. V., Sullivan, R. J., Chiarion‐Sileni, V., Nyakas, M., Kähler, K. C., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01121-y · Cited by 65
Self-citationOh, B., Boyle, F. M., Pavlakis, N., Clarke, S. J., Eade, T., Hruby, G., Lamoury, G., Carroll, S. L., Morgia, M., Kneebone, A. B., et al. (2021) · Cancers · doi:10.3390/cancers13194824 · Cited by 66
“For example, the three-year overall survival rates for melanoma patients receiving combination therapy, anti-PD-1, and anti-CTLA-4, were 58%, 52%, and 34%, respectively [9].”
BackgroundCell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Paderi, A., Giorgione, R., Giommoni, E., Mela, M., Rossi, V., Doni, L., Minervini, A., Carini, M., Pillozzi, S., & Antonuzzo, L. (2021) · Cancers · doi:10.3390/cancers13040860 · Cited by 62
“It has been reported that the incidence of irAEs is higher in ICI combination therapy than in monotherapy [12].”
BackgroundAlvarez-Breckenridge, C. A., Giobbie‐Hurder, A., Gill, C. M., Bertalan, M. S., Stocking, J. H., Kaplan, A. B., Nayyar, N., Lawrence, D. P., Flaherty, K. T., Shih, H. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0306 · Cited by 64
Melanoma and Vitiligo: In Good Company
Failla, C. M., Carbone, M. L., Fortes, C., Pagnanelli, G., & D’Atri, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225731 · Cited by 64
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
Tjulandin, S. A., Демидов, Л. В., Moiseyenko, V. M., Анатольевна, П. С., Semiglazova, Т. Y., Валентиновна, О. С., Zukov, R. A., Lazarev, S., Makarova, Y., Nechaeva, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.030 · Cited by 63
Falchook, G. S., Peeters, M., Rottey, S., Dirix, L. Y., Obermannova, R. L., Cohen, J. E., Perets, R., Frommer, R. S., Bauer, T. M., Wang, J. S.-Z., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01088-4 · Cited by 63
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 64
Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment
Huang, Y., Wang, H., Zhao, J., Wu, M., & Shih, T. (2021) · Biomolecules · doi:10.3390/biom11101398 · Cited by 67
“However, the response rates remain at only about 40% for melanoma [84,85], 25% for non-small-cell lung cancer [86], and <10% for most other cancer types [87].”
BackgroundTargeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance
Deng, J., Zhou, M. L., Liao, T., Kuang, W., Xia, H., Yin, Z., Tan, Q., Li, Y., Song, S., Zhou, E., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818453 · Cited by 63
Gordon, L. G., Leung, W. C. Y., Johns, R., McNoe, B., Lindsay, D., Merollini, K. M. D., Elliott, T. M., Neale, R. Ε., Olsen, C. M., Pandeya, N., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063178 · Cited by 64
Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances
Kim, H. J., & Kim, Y. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052984 · Cited by 69
PD-L1 expression in medulloblastoma: an evaluation by subgroup
Martin, A. M., Nirschl, C. J., Polanczyk, M. J., Bell, W. R., Nirschl, T. R., Harris‐Bookman, S., Phallen, J. A., Hicks, J. L., Martínez, D., Ogurtsova, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24951 · Cited by 65
“In fact, many tumors with expression levels of 1% or less have demonstrated objective clinical responses to this combination [47, 49].”
BackgroundTarhini, A. A., Lin, Y., Huang, L., Rahman, Z., Vallabhaneni, P., Mendiratta, P., Pingpank, J. F., Holtzman, M. P., Yusko, E. C., Rytlewski, J. A., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0428-5 · Cited by 68
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease
Kemeny, H. R., Elsamadicy, A. A., Farber, S. H., Champion, C. D., Lorrey, S., Chongsathidkiet, P., Woroniecka, K. I., Cui, X., Shen, S. H., Rhodin, K. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3486 · Cited by 63
Wang, S.-J., Khullar, K., Kim, S., Yegya‐Raman, N., Malhotra, J. D., Groisberg, R., Crayton, S. H., Silk, A. W., Nosher, J. L., Gentile, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000889 · Cited by 65
The current landscape of single-cell transcriptomics for cancer immunotherapy
Guruprasad, P., Lee, Y. G., Kim, K. H., & Ruella, M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201574 · Cited by 65
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer
Chang, A. E., Golob, J. L., Schmidt, T. M., Peltier, D. C., Lao, C. D., & Tewari, M. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.02.005 · Cited by 62
Self-citationKeeping Expectations in Check With Immune Checkpoint Inhibitors
Temel, J. S., Gainor, J. F., Sullivan, R. J., & Greer, J. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2146 · Cited by 62
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
Whelan, R., Prince, E. W., Gilani, A., & Hankinson, T. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020519 · Cited by 63
Kim, J., Hong, J., Lee, J., Lahiji, S. F., & Kim, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.002 · Cited by 62
Machiraju, D., Wiecken, M., Lang, N., Hülsmeyer, I., Roth, J., Schank, T. E., Eurich, R., Halama, N., Enk, A., & Hassel, J. C. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1926762 · Cited by 65
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 66
Sahu, A., Köse, K., Kraehenbuehl, L., Byers, C., Holland, A., Tembo, T., Santella, A., Alfonso, A., Li, M., Cordova, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32738-7 · Cited by 65
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Conway, J. W., Rawson, R. V., Lo, S., Ahmed, T., Vergara, I. A., Gide, T. N., Attrill, G. H., Carlino, M. S., Saw, R. P. M., Thompson, J. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004884 · Cited by 69
Self-citationShoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jaderberg, M. E. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2046 · Cited by 62
Self-citationDavies, D., Kamdar, S., Woolf, R., Zlatareva, I., Iannitto, M. L., Morton, C., Haque, Y., Martin, H., Biswas, D., Ndagire, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00690-0 · Cited by 67
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
Gao, X. Y., & McDermott, D. F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1513485 · Cited by 64
“major driver of clinical benefit from the combination [67].”
BackgroundT-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma
Leivonen, S., Pollari, M., Brück, O. E., Pellinen, T. S., Autio, M. I., Karjalainen‐Lindsberg, M., Mannisto, S., Kellokumpu‐Lehtinen, P., Kallioniemi, O., Mustjoki, S. M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.200105 · Cited by 63
“Antibodies targeting inhibitory molecules, such as PD-1, PD-L1, and CTLA-4 that regulate T-cell cytotoxicity have achieved impressive clinical responses.(27-29) However, despite clear clinical responses, only a fraction of patients respond to treatment.”
BackgroundRecent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Self-citationUveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
Castet, F., García‐Mulero, S., Pamplona, R. S., Cuellar, A., Casanovas, O., Mitjana, J. M. C., & Piulats, J. M. (2019) · Cancers · doi:10.3390/cancers11060834 · Cited by 64
“Moreover, combining anti-CTLA4 and anti-PD1 therapies has proved to significantly increase survival compared to anti-PD1 monotherapy [30].”
BackgroundBalaji, A., Zhang, J., Wills, B., Marrone, K. A., Elmariah, H., Yarchoan, M. M., Zimmerman, J. W., Hajjir, K., Venkatraman, D., Armstrong, D. K., et al. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00703 · Cited by 62
“Anti-CTLA monotherapy 0 (0) 0 (0) 4 (10) 1 (11) 4 (5) 1 (4)”
InfluentialTargeting B7‐1 in immunotherapy
Chen, R., Ganesan, A., Okoye, I., Arutyunova, E. I., Elahi, S., Lemieux, M. J., & Barakat, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21632 · Cited by 62
“Notably, the blockade of inhibitory receptors such as cytotoxic T lymphocyte antigen‐4 (CTLA‐4) and programmed cell death 1 (PD‐1) using monoclonal antibodies (mAbs) have revolutionized metastatic melanoma and lung cancer treatment.(5,6) The activation of naïve T‐cells is achieved through the interaction of the TCRs w…”
BackgroundPotential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma
Reese, M., Flammang, I., Yang, Z., & Dhayat, S. A. (2020) · Cancers · doi:10.3390/cancers12010197 · Cited by 63
Tiffen, J. C., Gallagher, S. J., Filipp, F. V., Gunatilake, D., Emran, A. A., Cullinane, C. M., Dutton‐Regester, K., Aoude, L. G., Hayward, N. K., Chatterjee, A., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.02.042 · Cited by 64
“Despite recent advances using immunotherapy and targeted therapies, not all patients respond to such treatments, and therapy resistance occurs in most initially responding patients (Eggermont et al., 2018; Long et al., 2018; Wolchok et al., 2017).”
BackgroundHargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 63
Patrinely, J. R., Young, A. C., Quach, H., Williams, G. R., Ye, F., Fan, R., Horn, L., Beckermann, K. E., Gillaspie, E. A., Sosman, J. A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.005 · Cited by 61
Self-citationWang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Bergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 58
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry
Martínez-Morilla, S., Villarroel‐Espíndola, F., Wong, P. F., Toki, M. I., Aung, T. N., Pelekanou, V., Bourke-Martin, B., Schalper, K. A., Kluger, H. M., & Rimm, D. L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3340 · Cited by 61
“Given the complexity of the tumor microenvironment (TME), high-multiplexing technologies may be valuable to discover novel candidate biomarkers linked to response or resistance to ICIs andmight uncover additional molecules targetable with new drug combinations.”
BackgroundInfluentialDeacon, D. C., Smith, E. A., & Judson‐Torres, R. L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642380 · Cited by 64
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
Fucà, G., Beninato, T., Bini, M., Mazzeo, L., Guardo, L. D., Cimminiello, C., Randon, G., Apollonio, G., Bisogno, I., Vecchio, M. D., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00819-0 · Cited by 60
Metadata
- Authors
- Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M. S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P. A., Long, G. V., Cebon, J., Sosman, J., Postow, M. A., Callahan, M. K., Walker, D., Rollin, L., Bhore, R., Hodi, F. S., & Larkin, J.
- Affiliations
- University of Siena (IT)
- From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.),...
- ORCID
- Wolchok, Jedd D.
- Gonzalez, Rene
- Rutkowski, Piotr
- Grob, Jean-Jacques
- Cowey, C. Lance
- Wagstaff, John
- Schadendorf, Dirk
- Ferrucci, Pier F.
- Smylie, Michael
- Dummer, Reinhard
- Hogg, David
- Haanen, John
- Carlino, Matteo S.
- Bechter, Oliver
- Maio, Michele
- Guidoboni, Massimo
- McArthur, Grant
- Ascierto, Paolo A.
- Long, Georgina V.
- Cebon, Jonathan
- Sosman, Jeffrey
- Postow, Michael A.
- Callahan, Margaret K.
- Bhore, Rafia
- Hodi, F. Stephen
- Larkin, James
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-05
- Volume
- 377
- Issue
- 14
- Pages
- 1345-1356
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5706778
- OpenAlex
- W2753432434
- Semantic Scholar
- 23dbeed54cde655fb6a12697b02c9ff303515da7
- Cited by
- 5,357
- References
- 18
- Citations by year
- 2026: 159 · 2025: 282 · 2024: 569 · 2023: 705 · 2022: 746 · 2021: 947 · 2020: 900 · 2019: 578 · 2018: 428 · 2017: 37
- FWCI
- 234.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- advanced melanoma, nivolumab, ipilimumab, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, overall survival, progression-free survival, treatment-related adverse events, immune-related adverse events, PD-L1 expression, BRAF mutation, long-term follow-up
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Humans, Melanoma, Middle Aged, Neoplasm Staging, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
